Pharmaceutical excipients influence the function of human uptake transporting proteins.
Although pharmaceutical excipients are supposed to be pharmacologically inactive, solubilizing agents like Cremophor EL have been shown to interact with cytochrome P450 (CYP)-dependent drug metabolism as well as efflux transporters such as P-glycoprotein (ABCB1) and multidrug resistance associated protein 2 (ABCC2). However, knowledge about their influence on the function of uptake transporters important in drug disposition is very limited. In this study we investigated the in vitro influence of polyethylene glycol 400 (PEG), hydroxypropyl-β-cyclodextrin (HPCD), Solutol HS 15 (SOL), and Cremophor EL (CrEL) on the organic anion transporting polypeptides (OATP) 1A2, OATP2B1, OATP1B1, and OATP1B3 and the Na(+)/taurocholate cotransporting polypeptide (NTCP). In stably transfected human embryonic kidney cells we analyzed the competition of the excipients with the uptake of bromosulfophthalein in OATP1B1, OATP1B3, OATP2B1, and NTCP, estrone-3-sulfate (E(3)S) in OATP1A2, OATP1B1, and OATP2B1, estradiol-17β-glucuronide in OATP1B3, and taurocholate (TA) in OATP1A2 and NTCP cells. SOL and CrEL were the most potent inhibitors of all transporters with the strongest effect on OATP1A2, OATP1B3, and OATP2B1 (IC(50) < 0.01%). HPCD also strongly inhibited all transport proteins but only for substrates containing a sterane-backbone. Finally, PEG seems to be a selective and potent modulator of OATP1A2 with IC(50) values of 0.05% (TA) and 0.14% (E(3)S). In conclusion, frequently used solubilizing agents were shown to interact substantially with intestinal and hepatic uptake transporters which should be considered in drug development. However, the clinical relevance of these findings needs to be evaluated in further in vivo studies.
Department of Clinical Pharmacology, Ernst-Moritz-Arndt-University Greifswald, 17487 Greifswald, Germany.
Anett
A
Engel
Stefan
S
Oswald
Werner
W
Siegmund
Markus
M
Keiser
D000073738:2-Hydroxypropyl-beta-cyclodextrin; D001692:Biological Transport / Q000187:drug effects; D002460:Cell Line; D004958:Estradiol / Q000031:analogs & derivatives / Q000378:metabolism; D004970:Estrone / Q000031:analogs & derivatives / Q000378:metabolism; D005079:Excipients / Q000494:pharmacology*; D005990:Glycerol / Q000031:analogs & derivatives / Q000494:pharmacology; D057809:HEK293 Cells; D006801:Humans; D000089762:Multidrug Resistance-Associated Protein 2; D027361:Organic Anion Transporters / Q000378:metabolism*; D029363:Organic Anion Transporters, Sodium-Dependent / Q000378:metabolism; D011092:Polyethylene Glycols / Q000494:pharmacology; D013229:Stearic Acids / Q000494:pharmacology; D013448:Sulfobromophthalein / Q000378:metabolism; D027981:Symporters / Q000378:metabolism; D013656:Taurocholic Acid / Q000378:metabolism; D047392:beta-Cyclodextrins / Q000494:pharmacology
C000715087:ABCC2 protein, human; D005079:Excipients; D000089762:Multidrug Resistance-Associated Protein 2; D027361:Organic Anion Transporters; D029363:Organic Anion Transporters, Sodium-Dependent; D013229:Stearic Acids; D027981:Symporters; D047392:beta-Cyclodextrins; D013448:Sulfobromophthalein; C071908:sodium-bile acid cotransporter; C025483:estradiol-17 beta-glucuronide; D000073738:2-Hydroxypropyl-beta-cyclodextrin; D004970:Estrone; D011092:Polyethylene Glycols; D004958:Estradiol; D013656:Taurocholic Acid; C067028:Solutol HS 15; C000515:cremophor EL; D005990:Glycerol; C017296:estrone sulfate